June 6th, 2008. Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance
The risk for pleural cancer, rather than showing an indefinite increase, might reach a plateau when a sufficiently long time has elapsed since exposure. The different trends for pleural and peritoneal cancer might be related to clearance of the asbestos from the workers' lungs.
January 6th, 2007. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial
4%. Our data show that TSP is a relatively effective second-line treatment in patients with progressive disease after systemic chemotherapy, with a low rate of major complications and treatment-related toxicity.
- Home
- About Mes-Line
- Categories
- Contact Us
- Glossary
- Processor
Article Categories
- Full Archive
- Type of Assessment:
- Case Study
- Causation
- Diagnosis & Differentiation
- Epidemiological
- General
- Staging
- Survival
- Symptoms & Symptom Management
- Treatment
- Angiogenesis
- Chemotherapy
- Bevacizumab (Avastatin)
- Carboplatin
- Cisplatin (Platinol ®)
- Coramsine
- Cyclophosphamide
- Cycloplatam
- Docetaxel (Taxotere)
- Doxorubicin
- Epirubicin (Ellence)
- Erlotinib (Tarceva®)
- Gemcitabine (Gemzar)
- Imatinib Mesylate (Gleevec/Glivec)
- Irinotecan
- melphalan
- mitomycin-C
- Oxaliplatin (Eloxatin)
- Oxaliplatine
- paclitaxel
- Pemetrexed (Alimta)
- Raltitrexed (Tomudex)
- Ranpirnase (Onconase)
- Selenite
- Sunitinib
- Taurolidine
- Vinorelbine
- Determining Efficacy
- EGFR
- Gene Therapy
- Immune-based Therapies
- Intraperitoneal Chemotherapy
- Intrapleural Chemotherapy
- Kinase Inhibitors
- New & Novel
- Photodynamic Therapy (PDT)
- pleurodesis
- Proteasome inhibitors
- Radiation
- Radiofrequency Ablation
- Signal Transduction Inhibitors
- Surgery
- Trimodality Therapy
- Type of Mesothelioma:
Annual Archives:
-
You are currently browsing the archives for the melphalan category.
